¿GPC Biotech AG, of Martinsried, Germany, said it will use its reverse genomics technology platform to perform modeof-action studies on up to 50 anti-bacterial compounds on behalf of Bayer AG, of Leverkusen. The project entails studiesof gene expression changes induced by both known and novel antibacterial compounds. Financial terms were not disclosed, but GPC retains the right to use expression profile data associated with compounds of known mode of action in other collaborations and in its internal programs.

¿Australian federal government officials decided to hold an inquiry over public concern that health insurance companies may be allowed to offer discounts to consumers with a “clean“ bill of genetic health - that is, genetic testing showing they have no predisposition toward certain diseases. The inquiry, expected to be a formal and substantial process, will look at the interaction between gene technology, privacy and human rights.

No Comments